Most Read Articles
Jairia Dela Cruz, 22 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
one month ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
Pearl Toh, 4 days ago
Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.
6 days ago
Mesalazine is not superior to placebo in terms of preventing recurrence in patients with diverticulitis, according to data from two phase III trials.

One-step SLK for polycystic disease is safe, feasible

3 months ago

Simultaneous liver and kidney transplantations (SLK) in polycystic diseases carried out through a one-step midline approach is effective, feasible, safe and may help avoid pre-transplant renal replacement therapy, a new study shows.

The study included 12 polycystic disease patients undergoing one-step SLK by midline laparotomy. Follow-up data including postoperative complications were evaluated against the 24 patients who received the classical two-step SLK.

The one-step SLK was carried out through a xiphopubic incision of the abdomen. Access to liver, native kidney and iliac fossae was achieved through bilateral cephalad retraction of the ribcage and lateral retraction of the abdominal wall.

The median follow-up for the 12 patients who received the midline laparotomy was 373 (120 to 684) days. Of these, 8 were performed with a bilateral nephrectomy and 4 with unilateral nephrectomy. No complications were recorded.

Between those who received one-step and two-step SLK, there were no statistically significant differences in donor and recipient body mass index, age and gender distribution, Model of End Stage Liver Disease scores and preoperative need for blood product transfusion.

All patients showed good signs of recovery and transplants were observed to function immediately. There was no significant difference in surgical complications within 90 days between the one-step and two-step SLK groups.

Finally, patient and graft outcomes and length of stay in the intensive care unit were not significantly different between the two groups. Two deaths were recorded in the two-step SLK group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 22 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
one month ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
Pearl Toh, 4 days ago
Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.
6 days ago
Mesalazine is not superior to placebo in terms of preventing recurrence in patients with diverticulitis, according to data from two phase III trials.